Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive agreement for SI-613. Having completed Phase II study, the product is presently in Phase III clinical development for use in the knee, to be followed by clinical studies for hip, ankle, elbow and shoulder and a long-term safety evaluation.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive...
Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive agreement for SI-613. Having completed Phase II study, the product is presently in Phase III clinical development for use in the knee, to be followed by clinical studies for hip, ankle, elbow and shoulder and a long-term safety evaluation.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
